following a full submission:
nivolumab (Opdivo®) is accepted for use within NHSScotland.
Indication under review: in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high colorectal cancer in the following setting: first-line treatment of unresectable or metastatic colorectal cancer.
In a phase III study of patients with untreated mismatch repair deficient or microsatellite instability-high unresectable or metastatic colorectal cancer, nivolumab plus ipilimumab significantly improved progression-free survival compared with investigator’s choice of chemotherapy.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- nivolumab (Opdivo)
- SMC ID:
- SMC2820
- Indication:
In combination with ipilimumab (YERVOY®) (NIVO + IPI) is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) colorectal cancer (CRC) in the following settings: first-line treatment of unresectable or metastatic CRC.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 19 January 2026